Business
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the
About this update from Novocure Limited
[{"type":"text","content":" ST. HELIER, Jersey--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held in New Orleans from April 8 to April 13, 2022. The research described in the presentations spans 10 tumor types and suggests the potential for broad usage of TTFields across multiple solid tumors.\n\nPresentation highlights include research on: transcriptomics (gene expression) analysis for identification of pathways that are activated in response to TTFields, concurrent treatment of ovarian cell lines with TTFields and PARP inhibitors, transient and reversible enhanced blood brain barrier permeability by TTFields in a human 3D in vitro model and efficacy of TTFields concomitant with radiation therapy in murine solid tumor models.\n\n“We believe ongoing research on Tumor Treating Fields suggests the potential for TTFields applicability across a variety of tumor types,” said Dr. Uri Weinberg, Novocure’s Chief Science Officer. “We are honored to participate in the exchange of scientific information and share new insights about the effects of TTFields on tumors, as revealed through a myriad of preclinical and clinical research, and treatment planning and modeling studies, by scientists around the world, at the AACR Annual Meeting.”\n\nPresentations from Novocure-sponsored and partner programs include:\n\n(Abstract #: CT234) PANOVA-3: A phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma. J. Finlay (Clinical Trials)\n\n(Abstract #: 4138) Prediction of progression-free survival in patients with primary glioblastoma: MRI T2 relaxivity and deep learning. A. Rulseh (Clinical Research Excluding Trials)\n\n(Abstract #: 3447) Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord. J. De Los Santos (Clinical Research Excluding Trials)\n\n(Abstract #: 3450) Impact of model inaccuracy on dose estimation in TTFields therapy. T. Marciano (Clinical Research Excluding Trials)\n\n(Abstract #: 1801) Application of Tumor Treating Fields (TTFields) to cancer cells enhances their membrane permeability. A. Haber (Experimental and Molecular Therapeutics)\n\n(Abstra...